VRTX vs ABBV

For growth investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger pick with 9.

6% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 27. 7x trailing P/E (22. 1x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 56 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 27.

7x versus AbbVie Inc. at 87. 0x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +104. 3%, compared to +98. 4% for Vertex Pharmaceuticals Incorporated (VRTX). Over 10 years, the gap is even starker: VRTX returned +405. 2% versus ABBV's +309. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Vertex Pharmaceuticals Incorporated's 0. 82β — meaning VRTX is approximately 142% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), Vertex Pharmaceuticals Incorporated (VRTX) is pulling ahead at 9.

6% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, VRTX leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus 32. 8% for ABBV. At the gross margin level — before operating expenses — VRTX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 5x forward P/E versus 22. 1x for Vertex Pharmaceuticals Incorporated — 7. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 30. 1% to $552. 27.

In this comparison, ABBV (3.

2% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +309. 7% 10Y return). Both have compounded well over 10 years (ABBV: +309. 7%, VRTX: +405. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VRTX is a mid-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.